R
Readystate Asset Management LP
+ HoldingMDLN
+11.43%
3M Return
$35.280
+0.642 (+1.82%)Al cierre
Loading chart…
- High
- 35.770
- Open
- 34.640
- VWAP
- 35.22
- Vol
- 5.71M
- Mkt Cap
- —
- Low
- 34.600
- Amount
- 201.23M
- EV/EBITDA, TTM
- 60.05
Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.
AI analysis of Medline Inc (MDLN)
buyMedline Inc. is a good buy right now due to its recent strong earnings performance, with a reported EPS of $0.50, beating expectations by $0.18, and a revenue of $7.7 billion for Q2, reflecting an 11.6% year-over-year growth. However, the risk lies in the lowered EBITDA outlook, now projected between $3.3 billion to $3.4 billion, which is below market expectations.
Métricas de valoración
The current forward P/E ratio for Medline Inc (MDLN) is 23.31, compared to its 5-year average forward P/E of 32.78.
Whales holding MDLN
Cronología de eventos
Noticias
7.008-18PRnewswireMedline Faces FDA Warning, Stock Plummets
7.008-13PRnewswireMedline Faces FDA Warning, Stock Drops Over 19%
7.008-07PRnewswireMedline Faces FDA Warning, Stock Drops Significantly
9.508-05seekingalphaMedline Reports Strong Q2 2026 Growth Amid Challenges
- 9.508-05seekingalpha
Medline Shares Plunge After Lowering EBITDA Outlook Despite Q2 Earnings Beat
MDLN FAQ — answered by Alphio AI
Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers. It operates in the Healthcare sector.
Medline Inc. is a good buy right now due to its recent strong earnings performance, with a reported EPS of $0.50, beating expectations by $0.18, and a revenue of $7.7 billion for Q2, reflecting an 11.6% year-over-year growth. However, the risk lies in the lowered EBITDA outlook, now projected between $3.3 billion to $3.4 billion, which is below market expectations.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.